Biogen
Biogen Inc. (Nasdaq: BIIB) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes medicines for serious and complex diseases, with a focus on neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for… From the company’s description.
In fiscal 2025, Biogen reported revenue of $9.89B, up 2.2% from fiscal 2024, and net income of $1.29B. Its operating margin was 19.2%, and operations generated $2.20B in cash. Over the twelve months to Jun 30, 2026, revenue was $10.03B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Biogen does
In the company’s own words
Biogen Inc. (Nasdaq: BIIB) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes medicines for serious and complex diseases, with a focus on neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for multiple sclerosis; SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedreich ataxia; and QALSODY for SOD1-associated amyotrophic lateral sclerosis. Through collaborations, Biogen shares in the commercialization of LEQEMBI for early Alzheimer’s disease and ZURZUVAE for postpartum depression, and holds business and financial rights to several anti-CD20 medicines, including OCREVUS, RITUXAN and GAZYVA. It also sells BENEPALI, IMRALDI and FLIXABI biosimilars, primarily in European markets. The company’s portfolio serves patients with neurological, psychiatric, immune-mediated and rare diseases, with products marketed directly and through commercial partners across the United States and international markets. Biogen supports its business through internal research and development, collaborations and acquisitions.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 875045
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Biogen — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Biogen · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Biogen’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Biogen’s bonds, as funds hold them
Funds report holding 7 issues of Biogen’s debt, $655.07M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.82%, maturing 2030 to 2055.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Biogen and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Biogen's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Biogen's last four quarterly filings that the numbers alone won't show?”